Home Companies Catalysts Deep Dives
Otezla apremilast APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaR&I
Launch2014-03-21
Peak Sales Est$2500M
Formulations[{"id":"otezla-oral","doses":"30mg tablet","route":"Oral","setting":"PATIENT_SELF","frequency":"BID"
Companies
AMGN (ORIGINATOR)100%
Mechanism: PDE4 inhibitor (oral)
Expert: Oral small molecule inhibitor of phosphodiesterase 4 (PDE4). Elevates intracellular cAMP, modulating cytokine production (TNF-alpha, IL-23, IL-17).
Everyday: Blocks an enzyme (PDE4) inside immune cells that controls inflammation. By inhibiting this enzyme, it reduces the inflammatory signals that cause skin plaques and joint swelling.
Targets: ["PDE4"]
Revenue History
PeriodRevenue ($M)
2024$2,126M
2025$2,265M
Q4 2024$624M
Q4 2025$625M
Programs (2)
IndicationStageKey StudyRegional Status
Plaque psoriasisAPPROVEDESTEEM-1/2[{"stage":"APPROVED","region":"US","approval_date":"2014-03-21"},{"stage":"APPRO
PsAAPPROVEDPALACE-1/2/3[{"stage":"APPROVED","region":"US","approval_date":"2014-03-21"}]
Notes
Acquired via Celgene portfolio. EU generic risk. US pricing pressure from 340B/Medicare Part D redesign.
Data from Supabase · Updated 2026-03-24